

**UNITED STATES DISTRICT COURT  
DISTRICT OF MASSACHUSETTS**

Astellas Institute for Regenerative Medicine, and  
Stem Cell & Regenerative Medicine International,  
Inc.,

Plaintiffs,

v.

ImStem Biotechnology, Inc.,  
Xiaofang Wang, and  
Ren-He Xu,

Defendants.

C.A. No. 1:17-cv-12239

**CORPORATE DISCLOSURE STATEMENT FOR  
STEM CELL & REGENERATIVE MEDICINE INTERNATIONAL INC.**

Pursuant to Rule 7.1 of the Federal Rules of Civil Procedure, and to enable Judges and Magistrate Judges of the Court to evaluate possible disqualification or recusal, the undersigned counsel for Plaintiff Stem Cell & Regenerative Medicine International Inc. (“SCRMI”) respectfully submits the following corporate disclosure statement.

More than 10% of Stem Cell & Regenerative Medicine International Inc. stock is owned by Astellas Institute for Regenerative Medicine, which is a wholly owned, indirect subsidiary of Astellas Pharma, Inc. Astellas Pharma Inc. is publicly traded on the Tokyo stock exchange. Astellas Pharma Inc. has no parent corporation, and no publicly-held corporation holds 10% or more of its stock. More than 10% of Stem Cell & Regenerative Medicine International Inc. stock is owned CHA Biotech Co., Ltd. (f/k/a CHA Bio and Diostech Co., Ltd.). CHA Biotech Co., Ltd. is publicly traded on the Korea stock exchange. CHA Biotech Co., Ltd. has no parent corporation, and no publicly-held corporation holds 10% or more of its stock.

Respectfully Submitted,

Dated: November 13, 2017

s/Sydney Pritchett

---

Sydney Pritchett  
Massachusetts Bar # 694195  
NIXON PEABODY LLP  
100 Summer Street  
Boston, MA 02110-2131  
(617) 345-1000  
SPritchett@nixonpeabody.com

*Attorneys for Plaintiff  
Stem Cell & Regenerative Medicine  
International, Inc.,*

Of Counsel:

Seth D. Levy  
SLevy@nixonpeabody.com  
Shawn G. Hansen  
SHansen@nixonpeabody.com  
NIXON PEABODY LLP  
300 South Grand Ave.  
Suite 4100  
Los Angeles, CA 90071-3151  
(213) 629-6000

**CERTIFICATE OF SERVICE**

I, Sydney Pritchett, do hereby certify that this document was filed through the ECF system on November 13, 2017 and will be served to Defendant via service of process.

/s/ Sydney Pritchett